Evidence map›Paper›PMID 35363872›Full record

ArticleBlood advances2022

Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network.

Simon Crouch, Daniel Painter, Sharon L Barrans, Eve Roman, Philip A Beer, Susanna L Cooke, Paul Glover, Suzan J L Van Hoppe, Nichola Webster, Stuart E Lacy and 7 more

Erratum issuedAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Audit of B-cell cancer genes.Blood advances · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Biology of follicular lymphoma: insights and windows of clinical opportunity.Hematology. American Society of Hematology. Education Program · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Simon CrouchEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom.ORCID 0000-0002-3026-2859
Daniel PainterEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom.ORCID 0000-0002-3936-7569
Sharon L BarransHaematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds, United Kingdom.
Eve RomanEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom.ORCID 0000-0001-7603-3704
Philip A BeerWellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom.
Susanna L CookeInstitute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
Paul GloverHaematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds, United Kingdom.
Suzan J L Van HoppeHaematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds, United Kingdom.
Nichola WebsterHaematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds, United Kingdom.
Stuart E LacyEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom.
Camilo RuizWellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom.ORCID 0000-0002-8395-2853
Peter J CampbellWellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom.
Daniel J HodsonWellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-6225-2033
Russell PatmoreQueen's Centre for Oncology and Haematology, Castle Hill Hospital, Cottingham, United Kingdom.
Cathy BurtonHaematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds, United Kingdom.
Alexandra SmithEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom.ORCID 0000-0002-1111-966X
Reuben M ToozeSection of Experimental Haematology, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom.ORCID 0000-0003-2915-7119

Funding

Cancer Research UK 29685
6 · The paper itself

Abstract

Follicular lymphoma (FL) is morphologically and clinically diverse, with mutations in epigenetic regulators alongside t(14;18) identified as disease-initiating events. Identification of additional mutational entities confirms this cancer's heterogeneity, but whether mutational data can be resolved into mechanistically distinct subsets remains an open question. Targeted sequencing was applied to an unselected population-based FL cohort (n = 548) with full clinical follow-up (n = 538), which included 96 diffuse large B-cell lymphoma (DLBCL) transformations. We investigated whether molecular subclusters of FL can be identified and whether mutational data provide predictive information relating to transformation. DNA extracted from FL samples was sequenced with a 293-gene panel representing genes frequently mutated in DLBCL and FL. Three clusters were resolved using mutational data alone, independent of translocation status: FL_aSHM, with high burden of aberrant somatic hypermutation (aSHM) targets; FL_STAT6, with high STAT6 & CREBBP mutation and low aSHM; and FL_Com, with the absence of features of other subtypes and enriched KMT2D mutation. Analysis of mutation signatures demonstrated differential enrichment of predicted mutation signatures between subgroups and a dominant preference in the FL_aSHM subgroup for G(C>T)T and G(C>T)C transitions consistent with previously defined aSHM-like patterns. Of transformed cases with paired samples, 17 of 26 had evidence of branching evolution. Poorer overall survival (OS) in the aSHM group (P = .04) was associated with older age; however, overall tumor genetics provided limited information to predict individual patient risk. Our approach identifies 3 molecular subclusters of FL linked to differences in underlying mechanistic pathways. These clusters, which may be further resolved by the inclusion of translocation status and wider mutation profiles, have implications for understanding pathogenesis as well as improving treatment strategies in the future.

Indexed as

Hematologic NeoplasmsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseHumansMutationTranslocation, GeneticUnited Kingdom

Identifiers

PMID35363872
PMCPMC9619185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.